Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE NovelMed Therapeutics, Inc.
BIO Investor Forum to be held October 8-9 in San Francisco, California
CLEVELAND, Oct. 7, 2013 /PRNewswire-USNewswire/ -- NovelMed Therapeutics, Inc. will be presenting at the 12th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 8-9 at the Palace Hotel in San Francisco, California.
NovelMed will provide an overview of its platform of high-affinity, humanized antibodies for the treatment of inflammatory, ophthalmic, and hemolytic diseases. NovelMed has used a variety of proprietary assays to identify a portfolio of humanized antibodies that selectively block the Alternative Pathway (AP) which is essential for optimal therapeutic efficacy. Follow-on preclinical safety studies of the Company's lead compounds in animal models have demonstrated no adverse effects.
NovelMed's lead compound is IND-ready and is expected to enter Phase I clinical trials in healthy volunteers in 2014 with subsequent trials specific for PNH and AMD. NovelMed has technology validation by the National Institute of Health on its inflammatory and hematological programs and has strong intellectual property on its portfolio of antibodies.
NovelMed Therapeutics, Inc. is a privately-held biotechnology company located in Cleveland, Ohio that is developing transformative treatments for orphan and non-orphan disease conditions. The Company's focus is on designing and developing superior treatments for complement-mediated inflammatory and hemolytic disorders including Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), ocular inflammation and vision loss (Dry & Wet AMD), arthritis (RA & OA), and cardiovascular diseases. NovelMed's drug candidates, differentiated by their unique mechanism(s) of action, are expected to deliver therapies with superior efficacy and enhanced safety and dosage profiles. NovelMed has developed a portfolio of antibody therapies that are suited for various clinical indications with a focus on unmet-needs.
About the Bio Investor Forum
The 12th Annual BIO Investor Forum is an international investor conference focused on private and emerging public biotech companies. Because its mission is to support industry-wide success, it presents a broad and unbiased view of investment opportunities. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and established biotechnology companies.
Press Release Contact for NovelMed:
Alexander McElroy, JD/MBA
Tel: (216) 712 5854
©2012 PR Newswire. All Rights Reserved.